- Ayala Pharmaceuticals Inc (NASDAQ:AYALA) reported data from Part A of its Phase 2 (RINGSIDE) trial evaluating AL102 in patients with desmoid tumors on Tuesday.
- At 16 weeks, one of 13 patients treated with AL102 demonstrated an unconfirmed partial response, which HC Wainwright believes signals encouraging initial activity.
- HC Wainwright reiterated the Buy rating on the stock with a price target of $18.
- The analyst says that Ayala's initial data is encouraging in the context of the clinical development landscape.
- Competitor SpringWorks Therapeutics Inc's (NASDAQ:SWTX) nirogacestat hadn't yet shown any responses during the 16-week timeframe.
- HC Wainwright awaits data on
- Disease control rate (DCR), as nirogacestat has shown 100% DCR in the Phase 2 trial on desmoid tumors.
- Longer-term data for AL102 benchmarked to the 29% (5/17) responses observed by approximately 28 months in SpringWorks' Phase 2 trial.
- Median progression-free survival as SpringWorks Phase 3 trial demonstrated a 71% reduction in the risk of progression vs. placebo.
- Breakdown in patients treated by each of three dose levels could add context to Ayala's unconfirmed response.
- Price Action: AYLA shares are up 8.25% at $1.18 during the market session on the last check Wednesday.
